Ubs Group Ag Astria Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 60,085 shares of ATXS stock, worth $573,811. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,085

Previous 65,674 8.51%

Holding current value

$573,811

Previous $597,000 10.72%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$8.97 - $12.65 $50,133 - $70,700	-5,589 Reduced 8.51%	60,085 $661,000
Q2 2024 Aug 13, 2024	SELL	$8.83 - $13.51 $533,102 - $815,652	-60,374 Reduced 47.9%	65,674 $597,000
Q1 2024 May 13, 2024	BUY	$6.99 - $16.69 $628,233 - $1.5 Million	89,876 Added 248.47%	126,048 $1.77 Million
Q4 2023 Feb 09, 2024	BUY	$4.42 - $8.06 $102,742 - $187,354	23,245 Added 179.82%	36,172 $277,000
Q3 2023 Nov 09, 2023	SELL	$6.89 - $9.86 $12,808 - $18,329	-1,859 Reduced 12.57%	12,927 $96,000
Q2 2023 Aug 11, 2023	BUY	$8.33 - $13.72 $100,909 - $166,204	12,114 Added 453.37%	14,786 $123,000
Q1 2023 May 12, 2023	BUY	$11.2 - $15.79 $29,881 - $42,127	2,668 Added 66700.0%	2,672 $35,000
Q4 2022 Feb 08, 2023	SELL	$7.44 - $14.89 $24,239 - $48,511	-3,258 Reduced 99.88%	4 $0
Q3 2022 Nov 10, 2022	BUY	$2.97 - $10.34 $9,613 - $33,470	3,237 Added 12948.0%	3,262 $29,000
Q2 2022 Aug 10, 2022	BUY	$2.46 - $6.96 $61 - $174	25 New	25 $0
Q1 2022 May 16, 2022	SELL	$3.92 - $7.1 $12,728 - $23,053	-3,247 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.08 - $8.62 $1,214 - $2,060	239 Added 7.95%	3,247 $18,000
Q3 2021 Nov 15, 2021	BUY	$7.32 - $12.9 $22,018 - $38,803	3,008 New	3,008 $27,000

Others Institutions Holding ATXS

# of Institutions

107

Shares Held

48.6M

Call Options Held

48K

Put Options Held

9.3K

View Full List

About Astria Therapeutics, Inc.

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $145M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

More about ATXS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account